Ludger Rose

4.9k total citations · 1 hit paper
33 papers, 1.5k citations indexed

About

Ludger Rose is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Ludger Rose has authored 33 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Surgery and 11 papers in Molecular Biology. Recurrent topics in Ludger Rose's work include Diabetes Treatment and Management (25 papers), Diabetes Management and Research (22 papers) and Pancreatic function and diabetes (16 papers). Ludger Rose is often cited by papers focused on Diabetes Treatment and Management (25 papers), Diabetes Management and Research (22 papers) and Pancreatic function and diabetes (16 papers). Ludger Rose collaborates with scholars based in Germany, United States and Denmark. Ludger Rose's co-authors include Stephen C. Bain, Vanita R. Aroda, J. Hans DeVries, Mads Axelsen, Milivoj Piletič, Bertrand Cariou, Everton Rowe, Helena W. Rodbard, Ildiko Lingvay and Eiichi Araki and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes Care and Diabetes.

In The Last Decade

Ludger Rose

30 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

2017 340 citations Vanita R. Aroda, Stephen C. Bain et al. The Lancet Diabetes & Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ludger Rose Germany	15	1.3k	573	450	241	157	33	1.5k
Kerensa Thorne United Kingdom	6	965 0.7×	239 0.4×	217 0.5×	84 0.3×	120 0.8×	13	1.4k
Robert Cuddihy United States	22	2.3k 1.8×	887 1.5×	731 1.6×	383 1.6×	374 2.4×	44	2.7k
Francis Chun Chung Chow Hong Kong	11	661 0.5×	296 0.5×	187 0.4×	127 0.5×	50 0.3×	16	855
Henriette Mersebach Denmark	18	1.1k 0.9×	192 0.3×	561 1.2×	59 0.2×	228 1.5×	33	1.4k
RM Bergenstal United States	4	1.6k 1.2×	380 0.7×	363 0.8×	99 0.4×	265 1.7×	10	1.7k
Bipin Sethi India	12	952 0.7×	485 0.8×	313 0.7×	198 0.8×	52 0.3×	44	1.2k
Heidrun Bosch‐Traberg Denmark	14	1.2k 0.9×	462 0.8×	425 0.9×	286 1.2×	38 0.2×	25	1.5k
Mark H. Schutta United States	18	463 0.4×	152 0.3×	383 0.9×	72 0.3×	215 1.4×	28	1.0k
Emily Gianatti Australia	11	495 0.4×	93 0.2×	108 0.2×	197 0.8×	52 0.3×	21	856
Matthew Wintle United States	12	1.4k 1.1×	637 1.1×	582 1.3×	308 1.3×	64 0.4×	18	1.6k

Countries citing papers authored by Ludger Rose

Since Specialization

Citations

This map shows the geographic impact of Ludger Rose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ludger Rose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ludger Rose more than expected).

Fields of papers citing papers by Ludger Rose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ludger Rose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ludger Rose. The network helps show where Ludger Rose may publish in the future.

Co-authorship network of co-authors of Ludger Rose

This figure shows the co-authorship network connecting the top 25 collaborators of Ludger Rose. A scholar is included among the top collaborators of Ludger Rose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ludger Rose. Ludger Rose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sordi, Valeria, Paolo Monti, Vito Lampasona, et al.. (2023). Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders. Frontiers in Endocrinology. 14. 1175640–1175640. 6 indexed citations

Piemonti, Lorenzo, Bart Keymeulen, Pieter Gillard, et al.. (2022). Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2 , in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial. Diabetes Obesity and Metabolism. 24(9). 1840–1849. 36 indexed citations

Parker, Victoria, Heike Schlichthaar, Fraser W. Gibb, et al.. (2022). Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. Diabetes Obesity and Metabolism. 24(7). 1360–1369. 56 indexed citations

Rose, Ludger, Gerhard Klausmann, & Alexander Seibold. (2020). Improving HbA1c Control in Type 1 or Type 2 Diabetes Using Flash Glucose Monitoring: A Retrospective Observational Analysis in Two German Centres. Diabetes Therapy. 12(1). 363–372. 15 indexed citations

Franek, Edward, Magnus Ekelund, Hak Chul Jang, et al.. (2020). 1034-P: Efficacy and Safety of Fast-Acting Insulin Aspart According to Baseline HbA1c in Adults with Type 2 Diabetes Treated with a Basal-Bolus Regimen. Diabetes. 69(Supplement_1).

Rose, Ludger, Takashi Kadowaki, Thomas R. Pieber, et al.. (2019). Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials. Diabetes Therapy. 10(3). 1029–1041. 3 indexed citations

Kröger, Janine, et al.. (2019). Effectiveness of FreeStyle Libre Flash Glucose Monitoring System Observed in Real-World, Chart Review Study in Adults with Type 2 Diabetes. Diabetologie und Stoffwechsel. 1 indexed citations

Buse, John B., Anders L. Carlson, Mitsuhisa Komatsu, et al.. (2018). Efficacy and Safety of Faster Aspart Compared with Insulin Aspart Both with Insulin Degludec in Adults with T1D. Diabetes. 67(Supplement_1). 1 indexed citations

Rabasa‐Lhoret, Rémi, Athena Philis‐Tsimikas, Bruce W. Bode, et al.. (2018). Improved Glycemic Control with Carbohydrate Counting for Adjustment of Fast-Acting Insulin Aspart vs. Insulin Aspart in Subjects with Type 1 Diabetes. Canadian Journal of Diabetes. 42(5). S8–S8.

10.

Rodbard, Helena W., Ildiko Lingvay, John H. Reed, et al.. (2018). Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. 103(6). 2291–2301. 292 indexed citations

11.

Aroda, Vanita R., Stephen C. Bain, Bertrand Cariou, et al.. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology. 5(5). 355–366. 340 indexed citations breakdown →

12.

Woo, Vincent, Chantal Mathieu, Bruce W. Bode, et al.. (2017). Efficacy and Safety of Fast-acting Insulin Aspart Are Maintained over 52 weeks: Comparison with Insulin Aspart in Onset 1. Canadian Journal of Diabetes. 41(5). S56–S57.

13.

Tsoukas, George, Stephen C. Bain, Eiichi Araki, et al.. (2017). Semaglutide Reduces HbA1c Across Baseline HbA1c Subgroups Across SUSTAIN 1–5 Clinical Trials. Canadian Journal of Diabetes. 41(5). S50–S50. 9 indexed citations

14.

Russell‐Jones, David, Bruce W. Bode, Christophe De Block, et al.. (2016). Double-Blind Mealtime Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Improves Glycemic Control in T1D: The Onset® 1 Trial. Canadian Journal of Diabetes. 40(5). S58–S58. 7 indexed citations

15.

Rodbard, Helena W., Ildiko Lingvay, John H. Reed, et al.. (2016). Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5). Canadian Journal of Diabetes. 40(5). S41–S42. 21 indexed citations

16.

Aroda, Vanita R., Stephen C. Bain, Bertrand Cariou, et al.. (2016). Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4). Diabetes Research and Clinical Practice. 120. S51–S51. 2 indexed citations

17.

Schernthaner, Guntram, Bruno Guerci, Baptist Gallwitz, et al.. (2010). Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes. Diabetes & Metabolism. 36(5). 389–394. 18 indexed citations

18.

Kazda, Christof, Baptist Gallwitz, Rafael Simó, et al.. (2009). The European Exenatide study of long‐term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes Obesity and Metabolism. 11(12). 1131–1137. 5 indexed citations

19.

Hatzichristou, Dimitrios, Eusebio Rubio‐Aurioles, Irène Buvat, et al.. (2008). Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabetic Medicine. 25(2). 138–146. 97 indexed citations

20.

Mann, J I, et al.. (1988). Blood lipid concentrations and other cardiovascular risk factors: distribution, prevalence, and detection in Britain. BMJ. 296(6638). 1702–1706. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact